We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Medpace (MEDP - Free Report) closed the most recent trading day at $543.57, moving +2.64% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.22%. At the same time, the Dow lost 0.03%, and the tech-heavy Nasdaq lost 0.66%.
Shares of the provider of outsourced clinical development services witnessed a gain of 18.85% over the previous month, beating the performance of the Medical sector with its gain of 6.47%, and the S&P 500's loss of 1.21%.
Market participants will be closely following the financial results of Medpace in its upcoming release. The company plans to announce its earnings on July 22, 2026. In that report, analysts expect Medpace to post earnings of $4.08 per share. This would mark year-over-year growth of 31.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $678.51 million, up 12.47% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Medpace. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, Medpace boasts a Zacks Rank of #3 (Hold).
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 31.08. This denotes a premium relative to the industry average Forward P/E of 15.95.
Also, we should mention that MEDP has a PEG ratio of 2.69. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical Services industry was having an average PEG ratio of 1.39.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
Medpace (MEDP - Free Report) closed the most recent trading day at $543.57, moving +2.64% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.22%. At the same time, the Dow lost 0.03%, and the tech-heavy Nasdaq lost 0.66%.
Shares of the provider of outsourced clinical development services witnessed a gain of 18.85% over the previous month, beating the performance of the Medical sector with its gain of 6.47%, and the S&P 500's loss of 1.21%.
Market participants will be closely following the financial results of Medpace in its upcoming release. The company plans to announce its earnings on July 22, 2026. In that report, analysts expect Medpace to post earnings of $4.08 per share. This would mark year-over-year growth of 31.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $678.51 million, up 12.47% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Medpace. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, Medpace boasts a Zacks Rank of #3 (Hold).
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 31.08. This denotes a premium relative to the industry average Forward P/E of 15.95.
Also, we should mention that MEDP has a PEG ratio of 2.69. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical Services industry was having an average PEG ratio of 1.39.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.